Background, The accumulation of advanced glycation end-products (AGEs) in e
nd-stage renal disease (ESRD) influenced by dialysis modalities is of curre
nt interest. Highly permeable membranes in haemodialysis or haemofiltration
should be able to eliminate circulating ACEs as well as their AGE precurso
rs more efficiently.
Methods. In our study, 10 non-diabetic and 10 diabetic ESRD patients were o
n haemodialysis with low-flux membranes (LF) followed by a cross-over haemo
dialysis with high-flux or super-flux polysulfone membranes (HF, SF) for 6
months each. We measured the protein-bound pentosidine and free pentosidine
serum levels by high-performance liquid chromatography (HPLC) as well as t
he serum AGE peptide, AGE-beta (2)-microglobulin and beta (2)-microglobulin
concentrations, using ELISA assays.
Results. Ail parameters investigated were significantly higher in dialysis
patients than in healthy subjects. The reduction rates during a single dial
ysis session were found to be higher using the SF than those obtained with
the HF (free pentosidine 82.4 +/- 7.3 cs 76.6 +/- 87%; AGE peptides 79.7 +/
- 7.7 vs 62.3 +/- 14.7%;, AGE-beta (2)-microglobulin 64.0 +/- 16.5 vs 45.4
+/- 17.7%; beta (2)-microglobulin 70.5 +/- 5.6 vs 58.2 +/- 6.0%). The prote
in-hound pentosidine levels remained constant over the respective dialysis
sessions, In the 6-month treatment period with the SF, decreased pre-dialys
is serum levels of protein-bound pentosidine, free pentosidine and AGE pept
ides were observed in nondiabetics and diabetics as compared with values ob
tained with the LF. The respective pre-dialysis AGE-beta (2)-microglobulin
concentrations decreased insignificantly, whereas those of beta (2)-microgl
obulin were significantly lower. Using the HF dialyser, only moderate chang
es of the parameters measured were noted.
Conclusion. Treatment with the biocompatible polysulfone SF dialyser seems
to be better suited to lower serum AGE levels and to eliminate their precur
sors.